292 related articles for article (PubMed ID: 15516858)
1. Beta blocker therapy after acute myocardial infarction in patients with heart failure and systolic dysfunction.
Thattassery E; Gheorghiade M
Heart Fail Rev; 2004 Apr; 9(2):107-13. PubMed ID: 15516858
[TBL] [Abstract][Full Text] [Related]
2. The effect of carvedilol in patients with impaired left ventricular systolic function following an acute myocardial infarction. How do the treatment effects on total mortality and recurrent myocardial infarction in CAPRICORN compare with previous beta-blocker trials?
Otterstad JE; Ford I
Eur J Heart Fail; 2002 Aug; 4(4):501-6. PubMed ID: 12167391
[TBL] [Abstract][Full Text] [Related]
3. Reappraisal of beta-blocker therapy in the acute and chronic post-myocardial infarction period.
Borrello F; Beahan M; Klein L; Gheorghiade M
Rev Cardiovasc Med; 2003; 4 Suppl 3():S13-24. PubMed ID: 14564230
[TBL] [Abstract][Full Text] [Related]
4. New evidence from the CAPRICORN Trial: the role of carvedilol in high-risk, post-myocardial infarction patients.
Sackner-Bernstein JD
Rev Cardiovasc Med; 2003; 4 Suppl 3():S25-9. PubMed ID: 14564231
[TBL] [Abstract][Full Text] [Related]
5. [Beta blockers in post-infarction state].
Schultheiss HP; Tschöpe C
Herz; 2002 Aug; 27 Suppl 1():26-9. PubMed ID: 12229255
[TBL] [Abstract][Full Text] [Related]
6. Switching to evidence-based once-daily beta-blockers for improved adherence to medication across the continuum of post-myocardial infarction left ventricular dysfunction and heart failure.
Abraham WT
Congest Heart Fail; 2008; 14(5):272-80. PubMed ID: 18983291
[TBL] [Abstract][Full Text] [Related]
7. Mortality and morbidity remain high despite captopril and/or Valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both after acute myocardial infarction: results from the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
White HD; Aylward PE; Huang Z; Dalby AJ; Weaver WD; Barvik S; Marin-Neto JA; Murin J; Nordlander RO; van Gilst WH; Zannad F; McMurray JJ; Califf RM; Pfeffer MA;
Circulation; 2005 Nov; 112(22):3391-9. PubMed ID: 16301343
[TBL] [Abstract][Full Text] [Related]
8. Are beta-blockers effective in patients who develop heart failure soon after myocardial infarction? A meta-regression analysis of randomised trials.
Houghton T; Freemantle N; Cleland JG
Eur J Heart Fail; 2000 Sep; 2(3):333-40. PubMed ID: 10938496
[TBL] [Abstract][Full Text] [Related]
9. Use of beta-blockers during and after myocardial infarction.
Aronow WS
Compr Ther; 1998; 24(6-7):327-31. PubMed ID: 9669097
[TBL] [Abstract][Full Text] [Related]
10. Design and rationale of the Danish trial of beta-blocker treatment after myocardial infarction without reduced ejection fraction: study protocol for a randomized controlled trial.
Kristensen AMD; Bovin A; Zwisler AD; Cerquira C; Torp-Pedersen C; Bøtker HE; Gustafsson I; Veien KT; Thomsen KK; Olsen MH; Larsen ML; Nielsen OW; Hildebrandt P; Foghmar S; Jensen SE; Lange T; Sehested T; Jernberg T; Atar D; Ibanez B; Prescott E
Trials; 2020 May; 21(1):415. PubMed ID: 32446298
[TBL] [Abstract][Full Text] [Related]
11. beta-Blocker therapy in heart failure.
Doughty RN
Heart Fail Monit; 2000; 1(1):2-7. PubMed ID: 12634875
[TBL] [Abstract][Full Text] [Related]
12. Association of beta-blocker treatment with mortality following myocardial infarction in patients with chronic obstructive pulmonary disease and heart failure or left ventricular dysfunction: a propensity matched-cohort analysis from the High-Risk Myocardial Infarction Database Initiative.
Coiro S; Girerd N; Rossignol P; Ferreira JP; Maggioni A; Pitt B; Tritto I; Ambrosio G; Dickstein K; Zannad F
Eur J Heart Fail; 2017 Feb; 19(2):271-279. PubMed ID: 27774703
[TBL] [Abstract][Full Text] [Related]
13. [Beta-blocker in secondary prevention of cardiovascular disease].
Sauer G
Z Kardiol; 2003 Jan; 92(1):24-30. PubMed ID: 12545298
[TBL] [Abstract][Full Text] [Related]
14. Landmark study: the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction Study (CAPRICORN).
Colucci WS
Am J Cardiol; 2004 May; 93(9A):13B-6B. PubMed ID: 15144931
[TBL] [Abstract][Full Text] [Related]
15. Treatments that improve outcome in the patient with heart failure, left ventricular systolic dysfunction, or both after acute myocardial infarction.
Weir R; McMurray JJ
Heart; 2005 May; 91 Suppl 2(Suppl 2):ii17-20; discussion ii31, ii43-8. PubMed ID: 15831602
[TBL] [Abstract][Full Text] [Related]
16. Angiotensin-converting enzyme inhibitors, beta-blockers, and mortality in systolic heart failure.
Thornton PL; Ahmed A
J Am Coll Cardiol; 2004 Apr; 43(7):1333; author reply 1333-4. PubMed ID: 15063454
[No Abstract] [Full Text] [Related]
17. Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials.
Shekelle PG; Rich MW; Morton SC; Atkinson CS; Tu W; Maglione M; Rhodes S; Barrett M; Fonarow GC; Greenberg B; Heidenreich PA; Knabel T; Konstam MA; Steimle A; Warner Stevenson L
J Am Coll Cardiol; 2003 May; 41(9):1529-38. PubMed ID: 12742294
[TBL] [Abstract][Full Text] [Related]
18. Mechanistic and clinical rationales for using beta-blockers in heart failure.
Bristow MR
J Card Fail; 2000 Jun; 6(2 Suppl 1):8-14. PubMed ID: 10908093
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive adrenergic blockade post myocardial infarction left ventricular dysfunction.
Fonarow GC
Cardiol Clin; 2008 Feb; 26(1):79-89, vii. PubMed ID: 18312908
[TBL] [Abstract][Full Text] [Related]
20. Additive beneficial effects of beta blockers in the prevention of symptomatic heart failure.
Genovesi Ebert A; Colivicchi F; Malvezzi Caracciolo M; Riccio C
Monaldi Arch Chest Dis; 2009 Mar; 72(1):18-22. PubMed ID: 19645208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
